PCT/US2004/035165





FIGURE 1B








FIG. 2B



WO 2005/042000 PCT/US2004/035165

FIGURE 3A

3/9






FIGURE 3B








FIGURE 4B







GPE treated group




FIGURE 4C

FIGURE 4D

WO 2005/042000 PCT/US2004/035165

:5/9. FIGURE 5A







FIGURE 5B

Effects of route administration







Fyure 6 B





FIGURE 7

FIGURE 8

Glypromate (3 mg/kg/h, i.v.) 24 - 28 h after injury



WO 2005/042000 PCT/US2004/035165

9/9

FIGURE 9



